This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Recently, Genomic Health (GHDX - Analyst Report) announced the positive result of a study on Oncotype DX to estimate the risk of loco-regional recurrence (LRR) in node-positive, estrogen receptor breast cancer patients, who were treated with adjuvant hormonal therapy and chemotherapy. The study was first presented in the 2013 Society of Surgical Oncology, Md.
Genomic Health encouragingly noted that Oncotype DX remains significantly effective for the ER-positive lymph node-positive breast cancer patients. According to the data, apart from identifying patents who will respond positively to adjuvant chemo-endocrine therapy, Oncotype DX can help the physicians’ decision on radiation treatment.
The company's lead product, the Oncotype DX breast cancer, has already been proved effective in predicting chemotherapy benefit in both node-negative and node-positive breast cancer. It is used to predict the likelihood of cancer recurrence in ductal carcinoma in situ (DCIS), patient survival within 10 years of diagnosis and chemotherapy benefit for early stage breast cancer patients.
The latest result will further enhance this product’s efficacy by finding the intensity and extent of radiation in breast cancer patients with node-positive disease.
As a global cancer company, Genomic Health is focused on the development and commercialization of genomic-based clinical tests for cancer diagnosis that enables physicians to make individualized treatment decisions. Banking on several strategies directed toward an increasing acceptance of the Oncotype DX breast test, Genomic is well placed to make the most of the huge market potential.
Earlier this month, the company announced the results of 2 studies, which were conducted to determine RNA-Sequencing and Mutation Identification. According to the results, DNA strand-of-origin information can help refine the process of identification of prognostic biomarkers, while gene mutations related to tumors can be tested with archival fixed paraffin embedded tumor (FPET) tissue, thus allowing an advanced tumor analysis process.
The company strongly believes that these findings will further strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of the future tests that combine both whole transcriptome profiling and mutation analysis.
Genomic Health carries a Zacks Rank #3 (Hold). Other medical device stocks worth a look are Given Imaging (GIVN - Snapshot Report), Medical Action Industries Inc. and Cytokinetics Incorporated (CYTK - Snapshot Report). All the stocks carry a Zacks Rank #1 (Strong Buy).